{'fraction_non_alphanumeric': 0.04715447154471545, 'fraction_numerical': 0.056910569105691054, 'mean_word_length': 5.484210526315789, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reactive perforating collagenosis during erlotinib therapy.

© 2012 The Authors. doi: 10.2340/00015555-1248 Journal Compilation © 2012 Acta Dermato-Venereologica. ISSN 0001-5555 Erlotinib is an epidermal growth factor receptor (EGF-R) tyrosine kinase inhibitor used for chemotherapy-resistant non-small cell lung cancer. Cutaneous toxicity is frequently seen, and the well-known adverse effects are dry skin, folliculitis, paronychia, and periungual granuloma (1). We describe here a case of reactive perforating collagenosis possibly triggered by erlotinib in a patient with well-controlled diabetes mellitus (DM).